<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38662650</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>Enterovirus virus-like-particle and inactivated poliovirus vaccines do not elicit substantive cross-reactive antibody responses.</ArticleTitle><Pagination><StartPage>e1012159</StartPage><MedlinePgn>e1012159</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1012159</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1012159</ELocationID><Abstract><AbstractText>Human enteroviruses are the most common human pathogen with over 300 distinct genotypes. Previous work with poliovirus has suggested that it is possible to generate antibody responses in humans and animals that can recognize members of multiple enterovirus species. However, cross protective immunity across multiple enteroviruses is not observed epidemiologically in humans. Here we investigated whether immunization of mice or baboons with inactivated poliovirus or enterovirus virus-like-particles (VLPs) vaccines generates antibody responses that can recognize enterovirus D68 or A71. We found that mice only generated antibodies specific for the antigen they were immunized with, and repeated immunization failed to generate cross-reactive antibody responses as measured by both ELISA and neutralization assay. Immunization of baboons with IPV failed to generate neutralizing antibody responses against enterovirus D68 or A71. These results suggest that a multivalent approach to enterovirus vaccination is necessary to protect against enterovirus disease in vulnerable populations.</AbstractText><CopyrightInformation>Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0001-7639-7276</Identifier><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paine</LastName><ForeName>Alden C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krug</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanekiyo</LastName><ForeName>Masaru</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruckwardt</LastName><ForeName>Tracy J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM129325</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="Y">Cross Reactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010215" MajorTopicYN="N">Papio</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="N">Enterovirus D, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>18</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>18</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>25</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38662650</ArticleId><ArticleId IdType="pmc">PMC11045126</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1012159</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-24-00289</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heckenberg E, Steppe JT, Coyne CB. Enteroviruses: The role of receptors in viral pathogenesis. Adv Virus Res. 2022;113: 89–110. doi: 10.1016/bs.aivir.2022.09.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.aivir.2022.09.002</ArticleId><ArticleId IdType="pubmed">36307169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinman AR, Koplan JP, Orenstein WA, Brink EW, Nkowane BM. Live or inactivated poliomyelitis vaccine: an analysis of benefits and risks. Am J Public Health. 1988;78: 291–295. doi: 10.2105/ajph.78.3.291</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/ajph.78.3.291</ArticleId><ArticleId IdType="pmc">PMC1349179</ArticleId><ArticleId IdType="pubmed">3277452</ArticleId></ArticleIdList></Reference><Reference><Citation>Garon JR, Cochi SL, Orenstein WA. The Challenge of Global Poliomyelitis Eradication. Infect Dis Clin North Am. 2015;29: 651–665. doi: 10.1016/j.idc.2015.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idc.2015.07.003</ArticleId><ArticleId IdType="pmc">PMC10544864</ArticleId><ArticleId IdType="pubmed">26610419</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, et al.. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014;14: 308–318. doi: 10.1016/S1473-3099(13)70342-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Passiak BS, Vogt MR, Wolf M, Sarma A, Vu N. A Severe Case of Enterovirus A71 Acute Flaccid Myelitis With Encephalitis. J Pediatr Infect Dis Soc. 2020;9: 777–780. doi: 10.1093/jpids/piaa067</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piaa067</ArticleId><ArticleId IdType="pubmed">32535628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapadia RK, Gill CM, Baca C, McMenamin C, Kannappan A, Niehaus WN, et al.. Enterovirus A71 causing meningoencephalitis and acute flaccid myelitis in a patient receiving rituximab. J Neuroimmunol. 2021;358: 577639. doi: 10.1016/j.jneuroim.2021.577639</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577639</ArticleId><ArticleId IdType="pubmed">34214953</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang L, Wang J, Zhang C, He W, Mo J, Zeng J, et al.. Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. Vaccine. 2020;38: 1804–1809. doi: 10.1016/j.vaccine.2019.12.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.12.025</ArticleId><ArticleId IdType="pubmed">31892446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Wong KT. Understanding Enterovirus 71 Neuropathogenesis and Its Impact on Other Neurotropic Enteroviruses. Brain Pathol. 2015;25: 614. doi: 10.1111/bpa.12279</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12279</ArticleId><ArticleId IdType="pmc">PMC8029433</ArticleId><ArticleId IdType="pubmed">26276025</ArticleId></ArticleIdList></Reference><Reference><Citation>Howson-Wells HC, Tsoleridis T, Zainuddin I, Tarr AW, Irving WL, Ball JK, et al.. Enterovirus D68 epidemic, UK, 2018, was caused by subclades B3 and D1, predominantly in children and adults, respectively, with both subclades exhibiting extensive genetic diversity. Microb Genomics. 8: 000825. doi: 10.1099/mgen.0.000825</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/mgen.0.000825</ArticleId><ArticleId IdType="pmc">PMC9465064</ArticleId><ArticleId IdType="pubmed">35532121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez A, Lee A, Guo A, Konopka-Anstadt JL, Nisler A, Rogers SL, et al.. Vital Signs: Surveillance for Acute Flaccid Myelitis—United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68: 608–614. doi: 10.15585/mmwr.mm6827e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6827e1</ArticleId><ArticleId IdType="pubmed">31295232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Zhuge J, Huang W, Nolan SM, Gilrane VL, Yin C, et al.. Enterovirus D68 Subclade B3 Strain Circulating and Causing an Outbreak in the United States in 2016. Sci Rep. 2017;7: 1242. doi: 10.1038/s41598-017-01349-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-01349-4</ArticleId><ArticleId IdType="pmc">PMC5430842</ArticleId><ArticleId IdType="pubmed">28455514</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilrane VL, Zhuge J, Huang W, Nolan SM, Dhand A, Yin C, et al.. Biennial Upsurge and Molecular Epidemiology of Enterovirus D68 Infection in New York, USA, 2014 to 2018. J Clin Microbiol. 2020;58: e00284–20. doi: 10.1128/JCM.00284-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00284-20</ArticleId><ArticleId IdType="pmc">PMC7448634</ArticleId><ArticleId IdType="pubmed">32493783</ArticleId></ArticleIdList></Reference><Reference><Citation>Duval M, Mirand A, Lesens O, Bay J-O, Caillaud D, Gallot D, et al.. Retrospective Study of the Upsurge of Enterovirus D68 Clade D1 among Adults (2014–2018). Viruses. 2021;13: 1607. doi: 10.3390/v13081607</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13081607</ArticleId><ArticleId IdType="pmc">PMC8402803</ArticleId><ArticleId IdType="pubmed">34452471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodcroft EB, Dyrdak R, Andrés C, Egli A, Reist J, Artola DGM de, et al.. Evolution, geographic spreading, and demographic distribution of Enterovirus D68. PLOS Pathog. 2022;18: e1010515. doi: 10.1371/journal.ppat.1010515</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010515</ArticleId><ArticleId IdType="pmc">PMC9212145</ArticleId><ArticleId IdType="pubmed">35639811</ArticleId></ArticleIdList></Reference><Reference><Citation>Schieble JH, Fox VL, Lennette EH. A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol. 1967;85: 297–310. doi: 10.1093/oxfordjournals.aje.a120693</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a120693</ArticleId><ArticleId IdType="pubmed">4960233</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma KC, Winn A, Moline HL, Scobie HM, Midgley CM, Kirking HL, et al.. Increase in Acute Respiratory Illnesses Among Children and Adolescents Associated with Rhinoviruses and Enteroviruses, Including Enterovirus D68—United States, July-September 2022. MMWR Morb Mortal Wkly Rep. 2022;71: 1265–1270. doi: 10.15585/mmwr.mm7140e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7140e1</ArticleId><ArticleId IdType="pmc">PMC9541033</ArticleId><ArticleId IdType="pubmed">36201400</ArticleId></ArticleIdList></Reference><Reference><Citation>Krug PW, Wang L, Shi W, Kong W-P, Moss DL, Yang ES, et al.. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci Adv. 2023;9: eadg6076. doi: 10.1126/sciadv.adg6076</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.adg6076</ArticleId><ArticleId IdType="pmc">PMC10191429</ArticleId><ArticleId IdType="pubmed">37196074</ArticleId></ArticleIdList></Reference><Reference><Citation>Andino R, Kirkegaard K, Macadam A, Racaniello VR, Rosenfeld AB. The Picornaviridae Family: Knowledge Gaps, Animal Models, Countermeasures, and Prototype Pathogens. J Infect Dis. 2023;228: S427–S445. doi: 10.1093/infdis/jiac426</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac426</ArticleId><ArticleId IdType="pubmed">37849401</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt MR, Fu J, Kose N, Williamson LE, Bombardi R, Setliff I, et al.. Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease. Sci Immunol. 2020. [cited 7 Feb 2022]. doi: 10.1126/sciimmunol.aba4902</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aba4902</ArticleId><ArticleId IdType="pmc">PMC7418079</ArticleId><ArticleId IdType="pubmed">32620559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Q, Zhu R, Xu L, He M, Yan X, Liu D, et al.. Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nat Microbiol. 2019;4: 124–133. doi: 10.1038/s41564-018-0275-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0275-7</ArticleId><ArticleId IdType="pmc">PMC6727974</ArticleId><ArticleId IdType="pubmed">30397341</ArticleId></ArticleIdList></Reference><Reference><Citation>Charnesky AJ, Faust JE, Lee H, Puligedda RD, Goetschius DJ, DiNunno NM, et al.. A human monoclonal antibody binds within the poliovirus receptor-binding site to neutralize all three serotypes. Nat Commun. 2023;14: 6335. doi: 10.1038/s41467-023-41052-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-41052-9</ArticleId><ArticleId IdType="pmc">PMC10564760</ArticleId><ArticleId IdType="pubmed">37816742</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur Huang K-Y, Chen M-F, Huang Y-C, Shih S-R, Chiu C-H, Lin J-J, et al.. Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children. Nat Commun. 2017;8: 762. doi: 10.1038/s41467-017-00736-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00736-9</ArticleId><ArticleId IdType="pmc">PMC5624920</ArticleId><ArticleId IdType="pubmed">28970483</ArticleId></ArticleIdList></Reference><Reference><Citation>You L, Chen J, Cheng Y, Li Y, Chen Y-Q, Ying T, et al.. Antibody signatures in hospitalized hand, foot and mouth disease patients with acute enterovirus A71 infection. PLOS Pathog. 2023;19: e1011420. doi: 10.1371/journal.ppat.1011420</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1011420</ArticleId><ArticleId IdType="pmc">PMC10263328</ArticleId><ArticleId IdType="pubmed">37262073</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K-YA, Zhou D, Fry EE, Kotecha A, Huang P-N, Yang S-L, et al.. Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71. Nat Commun. 2020;11: 5253. doi: 10.1038/s41467-020-19013-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19013-3</ArticleId><ArticleId IdType="pmc">PMC7567869</ArticleId><ArticleId IdType="pubmed">33067459</ArticleId></ArticleIdList></Reference><Reference><Citation>Shingler KL, Yoder JL, Carnegie MS, Ashley RE, Makhov AM, Conway JF, et al.. The Enterovirus 71 A-particle Forms a Gateway to Allow Genome Release: A CryoEM Study of Picornavirus Uncoating. PLOS Pathog. 2013;9: e1003240. doi: 10.1371/journal.ppat.1003240</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1003240</ArticleId><ArticleId IdType="pmc">PMC3605244</ArticleId><ArticleId IdType="pubmed">23555253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubeck D, Filman DJ, Hogle JM. Cryo-electron microscopy reconstruction of a poliovirus-receptor-membrane complex. Nat Struct Mol Biol. 2005;12: 615–618. doi: 10.1038/nsmb955</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb955</ArticleId><ArticleId IdType="pmc">PMC1500892</ArticleId><ArticleId IdType="pubmed">15965485</ArticleId></ArticleIdList></Reference><Reference><Citation>Elrick MJ, Pekosz A, Duggal P. Enterovirus D68 molecular and cellular biology and pathogenesis. J Biol Chem. 2021;296. doi: 10.1016/j.jbc.2021.100317</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100317</ArticleId><ArticleId IdType="pmc">PMC7949111</ArticleId><ArticleId IdType="pubmed">33484714</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sheng J, van Vliet ALW, Buda G, van Kuppeveld FJM, Rossmann MG. Molecular basis for the acid-initiated uncoating of human enterovirus D68. Proc Natl Acad Sci. 2018;115: E12209–E12217. doi: 10.1073/pnas.1803347115</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1803347115</ArticleId><ArticleId IdType="pmc">PMC6310856</ArticleId><ArticleId IdType="pubmed">30530701</ArticleId></ArticleIdList></Reference><Reference><Citation>Hovi T, Roivainen M. Peptide antisera targeted to a conserved sequence in poliovirus capsid VP1 cross-react widely with members of the genus Enterovirus. J Clin Microbiol. 1993;31: 1083–1087. doi: 10.1128/jcm.31.5.1083-1087.1993</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.31.5.1083-1087.1993</ArticleId><ArticleId IdType="pmc">PMC262883</ArticleId><ArticleId IdType="pubmed">8388885</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao LY, Pierce C, Gray-Johnson J, DeLotell J, Shaw C, Chapman N, et al.. Monoclonal antibodies to VP1 recognize a broad range of enteroviruses. J Clin Microbiol. 2009;47: 3108–3113. doi: 10.1128/JCM.00479-09</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00479-09</ArticleId><ArticleId IdType="pmc">PMC2756915</ArticleId><ArticleId IdType="pubmed">19710278</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld AB, Shen EQL, Melendez M, Mishra N, Lipkin WI, Racaniello VR. Cross-Reactive Antibody Responses against Nonpoliovirus Enteroviruses. mBio. 2022;13: e03660–21. doi: 10.1128/mbio.03660-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03660-21</ArticleId><ArticleId IdType="pmc">PMC8764532</ArticleId><ArticleId IdType="pubmed">35038922</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuelson A, Forsgren M, Johansson B, Wahren B, Sällberg M. Molecular basis for serological cross-reactivity between enteroviruses. Clin Diagn Lab Immunol. 1994;1: 336–341. doi: 10.1128/cdli.1.3.336-341.1994</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/cdli.1.3.336-341.1994</ArticleId><ArticleId IdType="pmc">PMC368258</ArticleId><ArticleId IdType="pubmed">7496972</ArticleId></ArticleIdList></Reference><Reference><Citation>Cello J, Samuelson A, Stålhandske P, Svennerholm B, Jeansson S, Forsgren M. Identification of group-common linear epitopes in structural and nonstructural proteins of enteroviruses by using synthetic peptides. J Clin Microbiol. 1993;31: 911–916. doi: 10.1128/jcm.31.4.911-916.1993</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.31.4.911-916.1993</ArticleId><ArticleId IdType="pmc">PMC263586</ArticleId><ArticleId IdType="pubmed">7681848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Fischer ER, Kouiavskaia D, Hansen BT, Ludtke SJ, Bidzhieva B, et al.. Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor. Proc Natl Acad Sci U S A. 2013;110: 20242–20247. doi: 10.1073/pnas.1320041110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1320041110</ArticleId><ArticleId IdType="pmc">PMC3864303</ArticleId><ArticleId IdType="pubmed">24277851</ArticleId></ArticleIdList></Reference><Reference><Citation>Puligedda RD, Kouiavskaia D, Al-Saleem FH, Kattala CD, Nabi U, Yaqoob H, et al.. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes. Vaccine. 2017;35: 5455–5462. doi: 10.1016/j.vaccine.2017.03.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2017.03.038</ArticleId><ArticleId IdType="pubmed">28343771</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy OC, Messacar K, Benson L, Bove R, Carpenter JL, Crawford T, et al.. Acute flaccid myelitis: cause, diagnosis, and management. Lancet Lond Engl. 2021;397: 334–346. doi: 10.1016/S0140-6736(20)32723-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32723-9</ArticleId><ArticleId IdType="pmc">PMC7909727</ArticleId><ArticleId IdType="pubmed">33357469</ArticleId></ArticleIdList></Reference><Reference><Citation>Pei J, Grishin NV. AL2CO: calculation of positional conservation in a protein sequence alignment. Bioinforma Oxf Engl. 2001;17: 700–712. doi: 10.1093/bioinformatics/17.8.700</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/17.8.700</ArticleId><ArticleId IdType="pubmed">11524371</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhillon S, Keam SJ. DTaP-IPV/Hib vaccine (Pentacel). Paediatr Drugs. 2008;10: 405–416. doi: 10.2165/0148581-200810060-00008</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/0148581-200810060-00008</ArticleId><ArticleId IdType="pubmed">18998751</ArticleId></ArticleIdList></Reference><Reference><Citation>FastStats. 10 Oct 2023 [cited 4 Dec 2023]. Available from: https://www.cdc.gov/nchs/fastats/immunize.htm.</Citation></Reference><Reference><Citation>HAN Archive—00474 | Health Alert Network (HAN). 16 Sep 2022 [cited 4 Dec 2023]. Available from: https://emergency.cdc.gov/han/2022/han00474.asp.</Citation></Reference><Reference><Citation>GHO | By category | Polio (Pol3)—Immunization coverage estimates by country. In: WHO [Internet]. World Health Organization; [cited 4 Dec 2023]. Available from: https://apps.who.int/gho/data/view.main.80601?lang=en.</Citation></Reference><Reference><Citation>Xiao J, Zhu Q, Yang F, Zeng S, Zhu Z, Gong D, et al.. The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China: A longitudinal surveillance study. J Infect. 2022;85: 428–435. doi: 10.1016/j.jinf.2022.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2022.06.020</ArticleId><ArticleId IdType="pubmed">35768049</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi S, Liao Q, Van Boeckel TP, Xing W, Sun J, Hsiao VY, et al.. Hand, Foot, and Mouth Disease in China: Modeling Epidemic Dynamics of Enterovirus Serotypes and Implications for Vaccination. PLoS Med. 2016;13: e1001958. doi: 10.1371/journal.pmed.1001958</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001958</ArticleId><ArticleId IdType="pmc">PMC4755668</ArticleId><ArticleId IdType="pubmed">26882540</ArticleId></ArticleIdList></Reference><Reference><Citation>Aw-Yong KL, NikNadia NMN, Tan CW, Sam I-C, Chan YF. Immune responses against enterovirus A71 infection: Implications for vaccine success. Rev Med Virol. 2019;29: e2073. doi: 10.1002/rmv.2073</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2073</ArticleId><ArticleId IdType="pubmed">31369184</ArticleId></ArticleIdList></Reference><Reference><Citation>He F, Rui J, Deng Z, Zhang Y, Qian K, Zhu C, et al.. Surveillance, Epidemiology and Impact of EV-A71 Vaccination on Hand, Foot, and Mouth Disease in Nanchang, China, 2010–2019.
Front Microbiol.
2022;12. Available from: https://www.frontiersin.org/articles/10.3389/fmicb.2021.811553. doi: 10.3389/fmicb.2021.811553

</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.811553</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2021.811553</ArticleId><ArticleId IdType="pmc">PMC8770912</ArticleId><ArticleId IdType="pubmed">35069515</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Liu Q, Ye X, Cai Y, Wang X, Shi J, et al.. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine. 2014;32: 4296–4303. doi: 10.1016/j.vaccine.2014.06.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2014.06.025</ArticleId><ArticleId IdType="pubmed">24950363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim P-Y, Hickey AC, Jamiluddin MF, Hamid S, Kramer J, Santos R, et al.. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine. 2015;33: 6017–6024. doi: 10.1016/j.vaccine.2015.05.108</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.05.108</ArticleId><ArticleId IdType="pubmed">26271825</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y, Daniell H. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines. Vaccine. 2017;35: 5418–5425. doi: 10.1016/j.vaccine.2016.12.061</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.12.061</ArticleId><ArticleId IdType="pmc">PMC5517362</ArticleId><ArticleId IdType="pubmed">28111147</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Ma Y, Xu Y, Yang H, Shi L, Che Y, et al.. Dynamic profiles of neutralizing antibody responses elicited in rhesus monkeys immunized with a combined tetravalent DTaP-Sabin IPV candidate vaccine. Vaccine. 2014;32: 1100–1106. doi: 10.1016/j.vaccine.2013.12.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.12.025</ArticleId><ArticleId IdType="pubmed">24412578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Nguyen MT, Currier MG, Jenkins JB, Strobert EA, Kajon AE, et al.. A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques. Nat Commun. 2016;7: 12838. doi: 10.1038/ncomms12838</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms12838</ArticleId><ArticleId IdType="pmc">PMC5036149</ArticleId><ArticleId IdType="pubmed">27653379</ArticleId></ArticleIdList></Reference><Reference><Citation>Stobart CC, Nosek JM, Moore ML. Rhinovirus Biology, Antigenic Diversity, and Advancements in the Design of a Human Rhinovirus Vaccine. Front Microbiol. 2017;8: 2412. doi: 10.3389/fmicb.2017.02412</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.02412</ArticleId><ArticleId IdType="pmc">PMC5723287</ArticleId><ArticleId IdType="pubmed">29259600</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowitz LE, Schiller JT. Human Papillomavirus Vaccines. J Infect Dis. 2021;224: S367–S378. doi: 10.1093/infdis/jiaa621</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa621</ArticleId><ArticleId IdType="pmc">PMC8577198</ArticleId><ArticleId IdType="pubmed">34590141</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Council (US) Committee for the Update of the Guide for theCare and Use of Laboratory Animals.
Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press (US); 2011. Available from: http://www.ncbi.nlm.nih.gov/books/NBK54050/</Citation></Reference><Reference><Citation>Madeira F, Pearce M, Tivey ARN, Basutkar P, Lee J, Edbali O, et al.. Search and sequence analysis tools services from EMBL-EBI in 2022. Nucleic Acids Res. 2022;50: W276–W279. doi: 10.1093/nar/gkac240</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkac240</ArticleId><ArticleId IdType="pmc">PMC9252731</ArticleId><ArticleId IdType="pubmed">35412617</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng EC, Goddard TD, Pettersen EF, Couch GS, Pearson ZJ, Morris JH, et al.. UCSF ChimeraX: Tools for structure building and analysis. Protein Sci. 2023;32: e4792. doi: 10.1002/pro.4792</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pro.4792</ArticleId><ArticleId IdType="pmc">PMC10588335</ArticleId><ArticleId IdType="pubmed">37774136</ArticleId></ArticleIdList></Reference><Reference><Citation>Hierholzer JC, Killington RA. 2—Virus isolation and quantitation. In: Mahy BW, Kangro HO, editors. Virology Methods Manual. London: Academic Press; 1996. pp. 25–46. doi: 10.1016/B978-012465330-6/50003-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-012465330-6/50003-8</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>